Pages that link to "Q35941081"

The following pages link to Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer (Q35941081):

Displaying 20 items.

• HER2 testing in gastric cancer: a practical approach (Q28256814) (← links)
• Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid (Q33378811) (← links)
• Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings. (Q34082392) (← links)
• Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. (Q34362184) (← links)
• Testing for her2 in breast cancer: current pathology challenges faced in Canada. (Q36416223) (← links)
• Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens (Q36646136) (← links)
• Benefits, issues, and recommendations for personalized medicine in oncology in Canada (Q37248023) (← links)
• Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? (Q37316222) (← links)
• Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). (Q37521326) (← links)
• Closing the personalized medicine information gap: HER2 test documentation practice (Q37573749) (← links)
• Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity (Q43249133) (← links)
• ErbB2 diagnostics in breast cancer--an update (Q51128557) (← links)
• A UK NEQAS ISH Multicenter Ring Study Using the Ventana HER2 Dual-Color ISH Assay (Q53162032) (← links)
• Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations. (Q54311896) (← links)
• Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients. (Q54322784) (← links)
• Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). (Q54538229) (← links)
• The HER2 gene copies per tumor cell either before or after correction for chromosome-17 correlated significantly with HER2 IHC results in epithelial ovarian cancer in a tissue microarray study (Q54635889) (← links)
• Unlocking bone for proteomic analysis and FISH (Q91117921) (← links)
• CellBlockistry: Chemistry and art of cell-block making - A detailed review of various historical options with recent advances (Q92323988) (← links)
• Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma (Q92890756) (← links)